Literature DB >> 22946707

Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance.

Andrea de Bartolomeis1, Giulio Perugi.   

Abstract

INTRODUCTION: Bipolar disorder is characterized by a complex set of symptoms, including recurrent manic, depressive or mixed episodes. Acute and long-term treatment of patients with bipolar disorder is mandatory to prevent symptom relapse and episode recurrences. Outcomes with monotherapy are often unsatisfactory in clinical practice, hence combinations of mood stabilizers and antipsychotics are widely utilized in patients showing no or partial response to, as well as intolerance to, monotherapies. This may offer a therapeutic advantage, however, the possibility of an increased incidence of side effects should be considered. AREAS COVERED: This paper reviews the current treatment guidelines for the treatment of bipolar disorder and examines the rationale behind the use of aripiprazole in combination with mood stabilizers for acute and long-term treatment of bipolar disorder. EXPERT OPINION: The combination of aripiprazole and mood stabilizers seems to offer an effective and relatively well-tolerated option for the treatment of acute mania and for the maintenance treatment of patients with bipolar I disorder. The combination presents a lower risk of metabolic side effects compared with other combination therapies, but increases the risk of extrapyramidal side effects with long-term treatment. The aripiprazole-valproate combination seems to be particularly promising in the treatment of patients with comorbidities such as anxiety and drug abuse, obsessive-compulsive disorder and bipolar disorder, as well as in mixed depressive disorder. Controlled trials are necessary in order to confirm these observations and to provide a useful insight for improving the use of drug combinations in bipolar patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22946707     DOI: 10.1517/14656566.2012.719876

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  6 in total

Review 1.  Korean Medication Algorithm for Bipolar Disorder 2014: comparisons with other treatment guidelines.

Authors:  Jong-Hyun Jeong; Jeong Goo Lee; Moon-Doo Kim; Inki Sohn; Se-Hoon Shim; Hee Ryung Wang; Young Sup Woo; Duk-In Jon; Jeong Seok Seo; Young-Chul Shin; Kyung Joon Min; Bo-Hyun Yoon; Won-Myong Bahk
Journal:  Neuropsychiatr Dis Treat       Date:  2015-06-26       Impact factor: 2.570

2.  Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials.

Authors:  Shuxin Luan; Hongquan Wan; Shijun Wang; He Li; Baogang Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2017-02-27       Impact factor: 2.570

3.  Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision.

Authors:  Young Sup Woo; Won-Myong Bahk; Jung Goo Lee; Jong-Hyun Jeong; Moon-Doo Kim; InKi Sohn; Se-Hoon Shim; Duk-In Jon; Jeong Seok Seo; Kyung Joon Min; Won Kim; Hoo-Rim Song; Bo-Hyun Yoon
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-11-30       Impact factor: 2.582

4.  Aripiprazole in the treatment of refractory mood disorders: a case series.

Authors:  Ather Muneer
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-08-12       Impact factor: 2.582

5.  Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.

Authors:  Elizabeth Brunner; Mauricio Tohen; Olawale Osuntokun; John Landry; Michael E Thase
Journal:  Neuropsychopharmacology       Date:  2014-05-07       Impact factor: 7.853

Review 6.  Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism.

Authors:  Andrea de Bartolomeis; Carmine Tomasetti; Felice Iasevoli
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.